ArrowArtboardCreated with Sketch.Title ChevronTitle ChevronIcon FacebookIcon LinkedinIcon Mail ContactPath LayerIcon MailPositive ArrowIcon PrintIcon Twitter

Japanese bioventures receiving healthy dose of investor funds

Top-tier bio startups rack up record market capitalization

TOKYO -- Japanese deregulation and partnerships with established drugmakers have led to a renaissance among domestic bioventures as investors shower funds in anticipation of the next big patent.

Forty-four major bioventures selected by Mizuho Securities had a combined market capitalization of 2.4 trillion yen ($21.7 billion) as of Tuesday, marking a new record.

Sponsored Content

About Sponsored Content This content was commissioned by Nikkei's Global Business Bureau.

Discover the all new Nikkei Asia app

  • Take your reading anywhere with offline reading functions
  • Never miss a story with breaking news alerts
  • Customize your reading experience

Nikkei Asian Review, now known as Nikkei Asia, will be the voice of the Asian Century.

Celebrate our next chapter
Free access for everyone - Sep. 30

Find out more